# An Open-label Study of EZYPRO® in Atrial Fibrillation Detection on ESUS Patients

Study · id `cardio:ct-nct05089435` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05089435](<https://clinicaltrials.gov/study/NCT05089435>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05089435

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 500 participants.

## Technical summary

Registry record NCT05089435. Allocation not applicable; no masking; primary purpose diagnostic. Start 2022-03-28 (actual); primary completion 2023-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase: Phase 4
- Enrolled: 500 participants (planned count; ClinicalTrials.gov record NCT05089435, source copy `cardio:ctgov-nct05089435-2022-05-10`, retrieved 2026-10-26)
- Started: 2022-03-28 (actual) (ClinicalTrials.gov record NCT05089435, source copy `cardio:ctgov-nct05089435-2022-05-10`, retrieved 2026-10-26)
- Primary completion: 2023-03 (anticipated) (ClinicalTrials.gov record NCT05089435, source copy `cardio:ctgov-nct05089435-2022-05-10`, retrieved 2026-10-26)
- Completion: 2023-12 (anticipated) (ClinicalTrials.gov record NCT05089435, source copy `cardio:ctgov-nct05089435-2022-05-10`, retrieved 2026-10-26)
- Countries: Taiwan (ClinicalTrials.gov record NCT05089435, source copy `cardio:ctgov-nct05089435-2022-05-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05089435-2022-05-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: An Open-label Study of EZYPRO® in Atrial Fibrillation Detection on ESUS Patients
- Condition: Atrial Fibrillation
- Condition: Embolic Stroke of Undetermined Source
- Intervention (Device): EZYPRO® ECG Recorder
- Lead sponsor: Sigknow Biomedical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)

## Provenance

Content hash: 9dc4f2507df5d175e1bdf21896486fcc51472c86fbcee7a6561f0c5b2bbf39d5
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
